The Future of Targeted Therapeutics: Key technologies, new therapy area applications and leading players
In recent years, the maximization of blockbuster revenues has been compromised by generic price erosion and a decline in new drug approvals. Large pharmaceutical companies are coming under pressure to explore new R&D strategies and implement more cost-effective sourcing methods for innovative new molecules.
The biotechnology industry is emerging as a hub of innovation for biomarker and new chemical entity (NCE) identification, and has become a vital component in the preclinical development of new drug technologies.
As therapy focus shifts to treating the causal pathway of disease and not merely the symptomology, the majority of emerging targeted therapeutics are large molecule biologics, while monoclonal antibody therapies represents the fastest growing segment within the pharmaceutical industry.
The Future of Targeted Therapeutics: Key technologies, new therapy area applications and leading players examines various types of targeted therapy within pharma pipelines, highlighting the molecules of greatest significance to major therapy areas. The key revenue drivers and product focus within targeted technology markets are also assessed.
This report also measures the impact of the new model of targeted therapeutic development upon stakeholder demand and health economics.
Discover the most promising targeted molecules within each therapeutic area, identify the pipeline potential of leading companies and align your R&D strategies with the latest innovations and development models...
Table of Contents
Download Table of Contents as a PDF
Other users found this report page using the following search terms: Targeted Therapeutics Targeted Therapies biologics antibodies antibody biotech
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.